MEDI 7836

Drug Profile

MEDI 7836

Alternative Names: Anti-IL-13 MAb-YTE; MEDI7836

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 12 Sep 2016 Discontinued - Phase-I for Asthma (In volunteers) in United Kingdom (SC)
  • 30 Apr 2016 MedImmune completes a phase I trial in Asthma (In volunteers) in the UK (NCT02388347)
  • 01 Mar 2015 Phase-I clinical trials in Asthma (In volunteers) in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top